> top > projects > LitCovid-sentences > docs > PMC:7187660 > annotations
LitCovid-sentences  

PMC:7187660 JSONTXT 19 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-67 Sentence denotes Clinical determinants for fatality of 44,672 patients with COVID-19
T2 69-229 Sentence denotes Using meta-analysis to explore clinical determinants for death of COVID-19 patients has been a problem due to insufficient sample size and overlapped cases [1].
T3 230-503 Sentence denotes In the study, we re-analyzed the largest confirmed case series reported publicly by the Chinese center for disease control and prevention (44,672 laboratory confirmed cases updated through February 11, 2020, [2]), to explore the clinical risk factors associated with death.
T4 504-606 Sentence denotes The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1.
T5 607-776 Sentence denotes Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up.
T6 777-891 Sentence denotes The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a).
T7 892-1039 Sentence denotes The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3].
T8 1040-1194 Sentence denotes Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p < 0.001) (see Fig. 1b).
T9 1195-1561 Sentence denotes Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p < 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p < 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p < 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p < 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.
T10 1562-1635 Sentence denotes Table 1 Characteristics between survivors and non-survivors with COVID-19
T11 1636-1744 Sentence denotes Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p
T12 1745-1755 Sentence denotes Age, n (%)
T13 1756-1785 Sentence denotes  0– 416 (0.9%) 0 416 (0.9%) 0
T14 1786-1825 Sentence denotes  10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2
T15 1826-1867 Sentence denotes  20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2
T16 1868-1912 Sentence denotes  30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2
T17 1913-1957 Sentence denotes  40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4
T18 1958-2006 Sentence denotes  50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3
T19 2007-2053 Sentence denotes  60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6
T20 2054-2098 Sentence denotes  70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0
T21 2099-2145 Sentence denotes  ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8
T22 2146-2162 Sentence denotes Severity*, n (%)
T23 2163-2211 Sentence denotes  Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0
T24 2212-2249 Sentence denotes  Severe 6168 (13.8%) 0 6168 (14.1%) 0
T25 2250-2300 Sentence denotes  Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0
T26 2301-2314 Sentence denotes Gender, n (%)
T27 2315-2391 Sentence denotes  Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) < 0.001
T28 2392-2445 Sentence denotes  Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7
T29 2446-2465 Sentence denotes Comorbidity#, n (%)
T30 2466-2546 Sentence denotes  Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) < 0.001
T31 2547-2620 Sentence denotes  Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) < 0.001
T32 2621-2707 Sentence denotes  Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) < 0.001
T33 2708-2789 Sentence denotes  Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) < 0.001
T34 2790-2855 Sentence denotes  Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006
T35 2856-2898 Sentence denotes *Missing data (n = 257 in survivors group)
T36 2899-2984 Sentence denotes #Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)
T37 2985-3058 Sentence denotes Fig. 1 Fatality rate distribution of age (a) and gender (b). ***p < 0.001
T38 3059-3244 Sentence denotes In summary, we found that there was no difference in the prevalence of COVID-19 between men and women, but male patients had a nearly 1.7-fold higher risk of death than female patients.
T39 3245-3337 Sentence denotes Moreover, we concluded that patients with comorbidities had a significantly high death risk.
T40 3338-3539 Sentence denotes Admittedly, due to the unavailability of individual patient data, we could not exclude the influence of age on the conclusion because old patients were more likely to have the underlying comorbidities.
T41 3540-3708 Sentence denotes We would like to provide a reminder to the physicians that more intensive surveillance or treatment should be considered for male patients and those with comorbidities.
T42 3709-3772 Sentence denotes Further and larger studies are needed to validate the findings.
T43 3774-3790 Sentence denotes Publisher’s Note
T44 3791-3909 Sentence denotes Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
T45 3911-3927 Sentence denotes Acknowledgements
T46 3928-3933 Sentence denotes None.
T47 3935-3957 Sentence denotes Authors’ contributions
T48 3958-4015 Sentence denotes GD and FZ conceptualized the idea and designed the study.
T49 4016-4049 Sentence denotes MY and XC revised the manuscript.
T50 4050-4101 Sentence denotes The authors read and approved the final manuscript.
T51 4103-4110 Sentence denotes Funding
T52 4111-4207 Sentence denotes This work was supported by the grants from the National Natural Science Foundation of China (No.
T53 4208-4221 Sentence denotes 81620108024).
T54 4223-4257 Sentence denotes Availability of data and materials
T55 4258-4273 Sentence denotes Not applicable.
T56 4275-4317 Sentence denotes Ethics approval and consent to participate
T57 4318-4333 Sentence denotes Not applicable.
T58 4335-4358 Sentence denotes Consent for publication
T59 4359-4374 Sentence denotes Not applicable.
T60 4376-4395 Sentence denotes Competing interests
T61 4396-4439 Sentence denotes All authors declare no competing interests.